Legend Biotech (LEGN) Non-Current Debt (2021 - 2025)

Legend Biotech (LEGN) has 5 years of Non-Current Debt data on file, last reported at $319.1 million in Q4 2025.

• Quarterly Non-Current Debt rose 5.94% year-over-year to $319.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $319.1 million (up 5.94% YoY) and the FY2025 annual result came in at $319.1 million, up 5.94% from the prior year.
• Non-Current Debt improved to $319.1 million in Q4 2025, from $171.9 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $319.1 million in Q4 2025 to a low of $17.3 million in Q2 2021.
• A 5-year average of $243.9 million and a median of $278.6 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt surged 116.61% — and 2025, when it sank 42.04%.
• Tracing LEGN's Non-Current Debt over 5 years: stood at $120.5 million in 2021, then surged by 116.61% to $260.9 million in 2022, then rose by 7.82% to $281.3 million in 2023, then climbed by 7.06% to $301.2 million in 2024, then climbed by 5.94% to $319.1 million in 2025.
• The last three Non-Current Debt figures came in at $319.1 million (Q4 2025), $171.9 million (Q3 2025), and $310.3 million (Q2 2025), per Business Quant data.